{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:38:59Z","timestamp":1769942339697,"version":"3.49.0"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.medcli.2025.107041","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T12:27:17Z","timestamp":1751459237000},"page":"107041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efectos adversos y otros aspectos de los f\u00e1rmacos con efecto incret\u00ednico"],"prefix":"10.1016","volume":"165","author":[{"given":"Maria D.","family":"Ballesteros-Pomar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0263-3728","authenticated-orcid":false,"given":"Irene","family":"Bret\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2025.107041_bib0360","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.medcli.2025.107041_bib0365","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.medcli.2025.107041_bib0375","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s10620-022-07536-2","article-title":"Retained food during esophagogastroduodenoscopy is a risk factor for gastric-to-pulmonary aspiration","volume":"68","author":"Feighery","year":"2023","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.medcli.2025.107041_bib0380","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2024.03.015","article-title":"Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use","volume":"167","author":"Yeo","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.medcli.2025.107041_bib0385","first-page":"453","article-title":"Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes","volume":"S1542\u20133565","author":"Barlowe","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.medcli.2025.107041_bib0390","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1111\/dom.15636","article-title":"Risks of peri- and postoperative complications with glucagon-like peptide-1 receptor agonists","volume":"26","author":"Klonoff","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2025.107041_bib0715","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s43440-024-00629-x","article-title":"A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment","volume":"76","author":"Tobaiqy","year":"2024","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.medcli.2025.107041_bib0395","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1001\/jama.2024.5003","article-title":"Preoperative GLP-1 Receptor Agonist Use and Risk of Postoperative Respiratory Complications","volume":"331","author":"Dixit","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2025.107041_bib0400","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/ALN.0000000000004776","article-title":"ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists","volume":"140","author":"Ushakumari","year":"2024","journal-title":"Anesthesiology"},{"key":"10.1016\/j.medcli.2025.107041_bib0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/clinem\/dgae719","article-title":"Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide","volume":"110","author":"Jalleh","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.medcli.2025.107041_bib0410","article-title":"Controversias de los efectos del tratamiento con agonistas del receptor de GLP-1 sobre el vaciamiento g\u00e1strico","author":"Rubio-Herrera","year":"2024","journal-title":"Endocrinol Diabetes Nutr"},{"key":"10.1016\/j.medcli.2025.107041_bib0415","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.medcli.2025.107041_bib0420","first-page":"124","article-title":"Acute pancreatitis due to different semaglutide regimens: An updated meta-analysis","volume":"71","author":"Masson","year":"2024","journal-title":"Endocrinol Diabetes Nutr (Engl Ed)"},{"key":"10.1016\/j.medcli.2025.107041_bib0720","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2025.107041_bib0425","doi-asserted-by":"crossref","first-page":"111806","DOI":"10.1016\/j.diabres.2024.111806","article-title":"The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis","volume":"215","author":"Lomeli","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.medcli.2025.107041_bib0430","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/MOG.0000000000001057","article-title":"Incretin mimetics and acute pancreatitis: Enemy or innocent bystander?","volume":"40","author":"Pratley","year":"2024","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.medcli.2025.107041_bib0435","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1038\/s41598-019-38956-2","article-title":"Glucagon-like peptide-1 receptor agonists and pancreatic cancer: A meta-analysis with trial sequential analysis","volume":"9","author":"Pinto","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.medcli.2025.107041_bib0440","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s12020-020-02223-6","article-title":"GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: Data from cardiovascular outcome trials","volume":"68","author":"Cao","year":"2020","journal-title":"Endocrine"},{"key":"10.1016\/j.medcli.2025.107041_bib0445","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwac021","article-title":"Glucagon-like peptide 1 receptor agonists and risk of anaphylactic reaction among patients with type 2 diabetes: A multisite population-based cohort study","volume":"191","author":"Pradhan","year":"2022","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.medcli.2025.107041_bib0450","first-page":"e181","article-title":"Cross-sectional analysis of adverse dermatologic events reported to the FDA after use of GLP-1 agonists","volume":"23","author":"Ituarte","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.medcli.2025.107041_bib0455","first-page":"403","article-title":"Glucagon-like peptide-1 receptor agonists and thyroid cancer: A narrative review","volume":"34","author":"Espinosa De Ycaza","year":"2024","journal-title":"Thyroid"},{"key":"10.1016\/j.medcli.2025.107041_bib0460","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/dci22-0052","article-title":"Putting GLP-1 RAs and thyroid cancer in context: Additional evidence and remaining doubts","volume":"46","author":"Thompson","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2025.107041_bib0465","doi-asserted-by":"crossref","first-page":"927859","DOI":"10.3389\/fendo.2022.927859","article-title":"Use of GLP-1 receptor agonists and occurrence of thyroid disorders: A meta-analysis of randomized controlled trials","volume":"13","author":"Hu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.medcli.2025.107041_bib0470","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.medcli.2025.107041_bib0475","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1111\/dom.16076","article-title":"Glucagon-like peptide 1 (GLP1) receptor agonists and risk for ischemic optic neuropathy: A meta-analysis of randomised controlled trials","volume":"2","author":"Silverii","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2025.107041_bib0480","doi-asserted-by":"crossref","first-page":"11","DOI":"10.59556\/japi.72.0621","article-title":"Nonarteritic anterior ischemic optic neuropathy and semaglutide: What is this all about?","volume":"72","author":"Singh","year":"2024","journal-title":"J Assoc Physicians India"},{"key":"10.1016\/j.medcli.2025.107041_bib0485","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1001\/jamaophthalmol.2024.2514","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","volume":"142","author":"Mollan","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.medcli.2025.107041_bib0490","unstructured":"European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists [Internet]. London: EMA; [updated 2024 Dec 28; cited 2024 Dec 28] Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-statement-ongoing-review-glp-1-receptor-agonists."},{"key":"10.1016\/j.medcli.2025.107041_bib0495","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/s11096-023-01694-7","article-title":"Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: A pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database","volume":"46","author":"Tobaiqy","year":"2024","journal-title":"Int J Clin Pharm"},{"key":"10.1016\/j.medcli.2025.107041_bib0500","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.medcli.2025.107041_bib0505","doi-asserted-by":"crossref","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon-like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.medcli.2025.107041_bib0510","doi-asserted-by":"crossref","first-page":"e2423385","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.medcli.2025.107041_bib0515","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1111\/dom.15864","article-title":"Association between glucagon-like peptide-1 receptor agonists and risk of suicidality: A comprehensive analysis of the global pharmacovigilance database","volume":"26","author":"Kim","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2025.107041_bib0520","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.7326\/M24-0329","article-title":"Glucagon-like peptide-1 receptor agonists and risk for suicidal ideation and behaviors in U.S. older adults with type 2 diabetes: A target trial emulation study","volume":"177","author":"Tang","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.medcli.2025.107041_bib0525","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.euroneuro.2024.07.001","article-title":"GLP-1 agonists and risk of suicidal thoughts and behaviours: confound by indication once again? A narrative review","volume":"87","author":"Strumila","year":"2024","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.medcli.2025.107041_bib0530","doi-asserted-by":"crossref","first-page":"e035948","DOI":"10.1161\/JAHA.124.035948","article-title":"Glucagon-like peptide-1 receptor agonism and suicide risk: Evidence from Mendelian randomization","volume":"13","author":"Zhao","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.medcli.2025.107041_bib0535","doi-asserted-by":"crossref","first-page":"e2423335","DOI":"10.1001\/jamanetworkopen.2024.23335","article-title":"GLP-1 receptor agonists and suicidality\u2014caution is needed","volume":"7","author":"Salvo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.medcli.2025.107041_bib0540","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1111\/dom.15794","article-title":"Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme","volume":"26","author":"Yale","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2025.107041_bib0545","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.medcli.2025.107041_bib0555","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2025.107041_bib0560","doi-asserted-by":"crossref","first-page":"156057","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.medcli.2025.107041_bib0565","article-title":"The effect of obesity pharmacotherapy on body composition, including muscle mass","author":"Argyrakopoulou","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.medcli.2025.107041_bib0570","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.medcli.2025.107041_bib0575","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/oby.23910","article-title":"Proportion of caloric restriction-induced weight loss as skeletal muscle","volume":"32","author":"Heymsfield","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.medcli.2025.107041_bib0580","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1161\/CIRCULATIONAHA.124.067676","article-title":"Muscle mass and glucagon-like peptide-1 receptor agonists: Adaptive or maladaptive response to weight loss?","volume":"150","author":"Linge","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.medcli.2025.107041_bib0585","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.medcli.2025.107041_bib0590","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"key":"10.1016\/j.medcli.2025.107041_bib0595","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.3390\/nu14122414","article-title":"Once-weekly semaglutide induces an early improvement in body composition in patients with type 2 diabetes: A 26-week prospective real-life study","volume":"14","author":"Volpe","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.medcli.2025.107041_bib0600","doi-asserted-by":"crossref","first-page":"377","DOI":"10.14740\/jocmr4987","article-title":"Oral semaglutide induces loss of body fat mass without affecting muscle mass in patients with type 2 diabetes","volume":"15","author":"Uchiyama","year":"2023","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.medcli.2025.107041_bib0605","doi-asserted-by":"crossref","first-page":"1386542","DOI":"10.3389\/fendo.2024.1386542","article-title":"Transforming body composition with semaglutide in adults with obesity and type 2 diabetes mellitus","volume":"15","author":"Rodr\u00edguez Jim\u00e9nez","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.medcli.2025.107041_bib0610","doi-asserted-by":"crossref","first-page":"1394506","DOI":"10.3389\/fendo.2024.1394506","article-title":"Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice","volume":"15","author":"Pantanetti","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.medcli.2025.107041_bib0615","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107041_bib0620","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.medcli.2025.107041_bib0725","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.2337\/dci24-0003","article-title":"Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity","volume":"47","author":"Drucker","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1016\/j.medcli.2025.107041_bib0625","doi-asserted-by":"crossref","first-page":"13662","DOI":"10.3390\/ijms222413662","article-title":"Obesity and bone: A complex relationship","volume":"22","author":"Rinonapoli","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.medcli.2025.107041_bib0635","doi-asserted-by":"crossref","first-page":"3361309","DOI":"10.1155\/2021\/3361309","article-title":"Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: A 52-week clinical study","volume":"2021","author":"Cai","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.medcli.2025.107041_bib0640","doi-asserted-by":"crossref","first-page":"1785321","DOI":"10.1155\/2024\/1785321","article-title":"Effects of glucagon-like peptide-1 receptor agonists on bone metabolism in type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"2024","author":"Li","year":"2024","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.medcli.2025.107041_bib0645","doi-asserted-by":"crossref","first-page":"e3168","DOI":"10.1002\/dmrr.3168","article-title":"Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials","volume":"35","author":"Cheng","year":"2019","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.medcli.2025.107041_bib0650","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s40618-024-02466-4","article-title":"Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: A retrospective cohort study from the Global Collaborative Network: Author list","volume":"48","author":"Nassar","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.medcli.2025.107041_bib0655","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.medcli.2023.05.021","article-title":"Effects of liraglutide among patients living with psoriasis and obesity","volume":"161","author":"Nicolau","year":"2023","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.medcli.2025.107041_bib0660","first-page":"e67232","article-title":"The role of glucagon-like peptide-1 agonists in the treatment of multiple sclerosis: a narrative review","volume":"16","author":"Kaye","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.medcli.2025.107041_bib0665","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: A scoping review","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.medcli.2025.107041_bib0670","doi-asserted-by":"crossref","first-page":"1462240","DOI":"10.3389\/fneur.2024.1462240","article-title":"Neuroprotective effects of GLP-1 class drugs in Parkinson's disease","volume":"15","author":"Lv","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.medcli.2025.107041_bib0675","doi-asserted-by":"crossref","first-page":"107220","DOI":"10.1016\/j.parkreldis.2024.107220","article-title":"GLP-1 receptor agonists for Parkinson's disease: An updated meta-analysis","volume":"130","author":"Albuquerque","year":"2025","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.medcli.2025.107041_bib0680","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13195-024-01666-7","article-title":"evoke and evoke+: Design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease","volume":"17","author":"Cummings","year":"2025","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.medcli.2025.107041_bib0685","doi-asserted-by":"crossref","first-page":"107312","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.medcli.2025.107041_bib0690","doi-asserted-by":"crossref","first-page":"e019562","DOI":"10.1136\/bmjopen-2017-019562","article-title":"Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: Study protocol of a randomised, double-blinded, placebo-controlled clinical trial","volume":"8","author":"Antonsen","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.medcli.2025.107041_bib0695","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.medcli.2025.107041_bib0700","doi-asserted-by":"crossref","DOI":"10.1111\/dom.16152","article-title":"Glucagon-like peptide-1 analogues reduce alcohol intake","author":"O\u2019Farrell","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.medcli.2025.107041_bib0705","doi-asserted-by":"crossref","first-page":"112424","DOI":"10.1016\/j.drugalcdep.2024.112424","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: A systematic review of randomized trials","volume":"264","author":"Martinelli","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.medcli.2025.107041_bib0710","doi-asserted-by":"crossref","first-page":"e151800","DOI":"10.1172\/JCI151800","article-title":"A randomized controlled trial of the GLP-1 receptor agonist dulaglutide in primary polydipsia","volume":"131","author":"Winzeler","year":"2021","journal-title":"J Clin Invest"}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325002696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775325002696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:43:47Z","timestamp":1753101827000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775325002696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0025775325002696"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107041","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efectos adversos y otros aspectos de los f\u00e1rmacos con efecto incret\u00ednico","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2025.107041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107041"}}